GILD:
The current market price stands at 123.16, unchanged from the previous close.
Support and Resistance Levels
The established support levels are 121.85, 121.50, and 121.00, while resistance levels are 124.50, 125.00, and 126.00. The pivot point is 123.16.
Indicators
The RSI indicates overbought at 63.89, with an ATR of 0.46982 showing increased volatility. SMA and EMA values trend positively, supporting potential gains.
Market Sentiment
Bullish trend predicted as price exceeds pivot point (123.16) and indicators favor upward movement.
GILD Signals & Technical Analysis
Last Updated: <% indicators.interval.updated|date:'MMM d, y h:mm:ss a' %>
Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics in areas of unmet medical need. Founded in 1987 and headquartered in Foster City, California, Gilead has established itself as a leader in the development of antiviral drugs that combat HIV, hepatitis B and C, influenza, and COVID-19. With a commitment to advancing global health, Gilead's research and development efforts focus on creating transformative medicines for patients worldwide.
Over the years, Gilead has built a strong market position, particularly in the field of antiviral therapies. The company gained widespread recognition for its groundbreaking treatments, including the antiretroviral therapy Truvada, which has played a crucial role in combating the HIV epidemic. Additionally, Gilead's innovative approach to hepatitis C treatment, notably with its drug Harvoni, revolutionized care practices and significantly reduced the disease's prevalence. As of 2023, Gilead continues to strengthen its presence in the market with robust pipelines that encompass other therapeutic areas, including oncology and inflammation.
In terms of financial performance, Gilead Sciences has demonstrated resilience amidst a dynamic healthcare landscape. The company reported a revenue of $27 billion for the fiscal year 2022, reflecting a steady demand for its key products despite emerging competition. Gilead's strategic investments in research and development have positioned it for sustained growth, with an R&D expenditure exceeding $5 billion in the same year. This commitment underscores Gilead's focus on innovation and its ability to adapt to changing healthcare needs.
Gilead Sciences is also recognized for its global initiatives aimed at expanding access to its therapies, particularly in low- and middle-income countries. The company's partnerships with various organizations, including governments and non-profits, highlight its dedication to improving health outcomes worldwide. As Gilead continues to evolve, it remains committed to delivering cutting-edge solutions that enhance the quality of life for patients everywhere.
<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
